News | Ablation Systems | February 02, 2016

Abbott Acquires Kalila Medical to Expand Cardiac Electrophysiology Offerings

Acquisition gives Abbott access to Kalila Medical’s novel steerable sheath for catheter-based EP procedures

Abbott, Kalila Medical, acquisition, electrophysiology offerings

Vado Steerable Introducer Sheath image courtesy of Kalila Medical

February 2, 2016 — Abbott announced that it has acquired private medical device company Kalila Medical Inc. Kalila Medical is a developer of next-generation access technologies used in cardiac electrophysiology procedures for the treatment of heart rhythm disorders, including atrial fibrillation. Financial terms were not disclosed.

Kalila Medical, headquartered in Campbell, Calif., has developed a novel steerable sheath that helps physicians more easily access and perform catheter-based electrophysiology procedures. The company’s proprietary technology features an innovative design that eliminates whipping from torque buildup experienced with other sheath designs. The sheath also provides optimal navigation stability during cardiac ablation procedures, enabling precise left atrial access and maneuverability, with the potential to decrease procedure time.  

"Atrial fibrillation is a serious condition that increases the risk of stroke and causes severe symptoms in many patients, but remains undertreated today because current technologies have limited effectiveness," said Michael Pederson, general manager of Abbott's electrophysiology business. "With this acquisition, Abbott gains a unique technology to expand our portfolio of tools for the treatment of atrial fibrillation and other heart rhythm disorders. We look forward to initiating the launch of this innovative sheath in the United States and Europe in the coming weeks."

In 2014, Abbott acquired Topera, a company developing innovative electrophysiology technologies, which identify and locate rotors – the unique patient-specific sources that sustain serious heart rhythm disorders, including atrial fibrillation. With the ability to visualize individual rotors, physicians can tailor treatment approaches for each patient. Abbott released a new software update providing enhanced rotor visualization, which is designed to improve the efficiency of physiologic rotor mapping, in January 2016.

Kalila received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its steerable introducer sheath in 2014 and received CE Mark in December 2013. 

For more information: www.abbottvascular.com

Related Content

Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems| December 08, 2017
December 7, 2017 — Stereotaxis Inc.
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
CardioFocus, HeartLight Excalibur Balloon, 22nd Annual AF Symposium, atrial fibrillation, initial clinical evaluation
News | Ablation Systems| January 25, 2017
CardioFocus Inc. recently announced the initial clinical evaluation of the HeartLight Excalibur Balloon, a next-...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems| November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Overlay Init